Outsourcing in Clinical Trials New England 20147-8 October 2014, Boston, MA
Welcome to the flagship event in our global Outsourcing in Clinical Trials Series. Last year over 400 pharmaceutical, biotechnology and medical device professionals attended Outsourcing in Clinical Trials New England event to learn from case-study based presentations, network with their peers, discover new solutions and services and find answers to all of their clinical challenges.
With such enthusiasm around this conference, this October’s event will once again bring together the industry leaders from within this hub for two days of presentations, case studies, panel discussions and roundtables, alongside the networking opportunity. With over 50 speakers participating, the content will cover all aspects of clinical outsourcing from informed sourcing and efficient contract negotiation through to effective management, monitoring and communication techniques.
Whether you are a senior professional in a global pharmaceutical company or a smaller company looking to expand, access to insight and knowledge about the latest pharmaceutical trends is vital.
The Outsourcing Clinical Trial series is growing every year. View the full list of upcoming events to make sure you don’t miss any news. The list of websites will be updated as soon as new events are live so check back regularly
We are always happy to see photos taken at our events! If you have any you would like to submit, please email firstname.lastname@example.org The Arena Team
Primary delegates for this event are those with responsibility for clinical outsourcing decisions and strategy within biotechnology, pharmaceutical, virtual and medical device companies throughout Southern California.
Outsourcing in Clinical Trials New England boasts a fantastic exhibition of clinical service providers and industry specialists. Our exhibition area is already filling up due to the fantastic launch event which took place this year. If you have a service or solution you would like to promote at this event, please use the details below to make contact with our commercial team.
US-based Auspex Pharmaceuticals has completed enrolment of the planned 90 patients in its Phase III registration clinical trial (First-HD) of SD-809 to treat chorea associated with Huntington's disease (HD).
ARCA biopharma (ABIO) has received acceptance from Health Canada for its clinical trial application (CTA) for the GENETIC-AF clinical trial evaluating Gencaro to treat atrial fibrillation (AF).
UK-based AstraZeneca has initiated the Phase III programme for tralokinumab, a potential treatment for patients with severe, inadequately controlled asthma.
US-based biopharmaceutical firm TG Therapeutics has initiated a new triple therapy clinical trial combining two of its experimental drugs, TG-1101, a glycoengineered anti-CD20 monoclonal antibody, and TGR-1202, a PI3K delta inhibitor, with the market…
The US Food and Drug Administration (FDA) has agreed on the design of US-based pharmaceutical firm CorMedix's pivotal Phase III protocol for Neutrolin to treat Hemodialysis patients.
Amgen and its subsidiary Onyx Pharmaceuticals have reported top-line results from Phase III Focus trial of Kyprolis in patients with relapsed and advanced refractory multiple myeloma.